Literature DB >> 16753024

Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.

Frederic Morvan1, Kim Boulukos, Philippe Clément-Lacroix, Sergio Roman Roman, Isabelle Suc-Royer, Béatrice Vayssière, Patrick Ammann, Patrick Martin, Sonia Pinho, Philippe Pognonec, Patrick Mollat, Christof Niehrs, Roland Baron, Georges Rawadi.   

Abstract

UNLABELLED: Wnt/beta-catenin signaling has been proven to play a central role in bone biology. Unexpectedly, the Wnt antagonist Dkk2 is required for terminal osteoblast differentiation and mineralized matrix formation. We show that Dkk1, unlike Dkk2, negatively regulates osteoblast differentiation and bone formation.
INTRODUCTION: The Wnt co-receptor LRP5 is a critical regulator of bone mass. Dickkopf (Dkk) proteins act as natural Wnt antagonists by bridging LRP5/6 and Kremen, inducing the internalization of the complex. Wnt antagonists are thus expected to negatively regulation bone formation. However, Dkk2 deficiency results in increased bone, questioning the precise role of Dkks in bone metabolism.
MATERIALS AND METHODS: In this study, we investigated specifically the role of Dkk1 in bone in vitro and in vivo. Using rat primary calvaria cells, we studied the effect of retroviral expression of Dkk1 on osteoblast differentiation. In addition, the effect of Dkk1 osteoblast was studied in MC3T3-E1 cells by means of recombinant protein. Finally, to address the role of Dkk1 in vivo, we analyzed the bone phenotype of Dkk1(+/-) animals.
RESULTS: Retroviral expression of Dkk1 in rat primary calvaria cells resulted in a complete inhibition of osteoblast differentiation and formation of mineralized nodules, with a marked decrease in the expression of alkaline phosphatase. Dkk1 expression also increased adipocyte differentiation in these cell cultures. Recombinant murine Dkk1 (rmDkk1) inhibited spontaneous and induced osteoblast differentiation of MC3T3-E1 cells. To determine the role of Dkk1 in vivo and overcome the embryonic lethality of homozygous deletion, we studied the bone phenotype in heterozygous Dkk1-deficient mice. Structural, dynamic, and cellular analysis of bone remodeling in Dkk1(+/-) mice showed an increase in all bone formation parameters, with no change in bone resorption, leading to a marked increase in bone mass. Importantly, the number of osteoblasts, mineral apposition, and bone formation rate were all increased several fold.
CONCLUSIONS: We conclude that Dkk1 protein is a potent negative regulator of osteoblasts in vitro and in vivo. Given that a heterozygous decrease in Dkk1 expression is sufficient to induce a significant increase in bone mass, antagonizing Dkk1 should result in a potent anabolic effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16753024     DOI: 10.1359/jbmr.060311

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  220 in total

1.  Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo.

Authors:  Helmut Glantschnig; Richard A Hampton; Ping Lu; Jing Z Zhao; Salvatore Vitelli; Lingyi Huang; Peter Haytko; Tara Cusick; Cheryl Ireland; Stephen W Jarantow; Robin Ernst; Nan Wei; Pascale Nantermet; Kevin R Scott; John E Fisher; Fabio Talamo; Laura Orsatti; Alfred A Reszka; Punam Sandhu; Donald Kimmel; Osvaldo Flores; William Strohl; Zhiqiang An; Fubao Wang
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

Review 2.  Update on Wnt signaling in bone cell biology and bone disease.

Authors:  David G Monroe; Meghan E McGee-Lawrence; Merry Jo Oursler; Jennifer J Westendorf
Journal:  Gene       Date:  2011-11-03       Impact factor: 3.688

Review 3.  Osteoblastogenesis regulation signals in bone remodeling.

Authors:  C Zuo; Y Huang; R Bajis; M Sahih; Y-P Li; K Dai; X Zhang
Journal:  Osteoporos Int       Date:  2012-06       Impact factor: 4.507

Review 4.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

5.  Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice.

Authors:  Gang-Qing Yao; Jian-Jun Wu; Nancy Troiano; Karl Insogna
Journal:  J Bone Miner Metab       Date:  2010-07-03       Impact factor: 2.626

Review 6.  Wnt signaling and the control of human stem cell fate.

Authors:  J K Van Camp; S Beckers; D Zegers; W Van Hul
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

7.  Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts.

Authors:  Rongrong Zhang; Babatunde O Oyajobi; Stephen E Harris; Di Chen; Christopher Tsao; Hong-Wen Deng; Ming Zhao
Journal:  Bone       Date:  2012-09-29       Impact factor: 4.398

Review 8.  WNT Signaling in osteoarthritis and osteoporosis: what is the biological significance for the clinician?

Authors:  Liesbet Lodewyckx; Rik J U Lories
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 9.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

10.  Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis.

Authors:  Zandra A Jenkins; Margriet van Kogelenberg; Tim Morgan; Aaron Jeffs; Ryuji Fukuzawa; Esther Pearl; Christina Thaller; Anne V Hing; Mary E Porteous; Sixto Garcia-Miñaur; Axel Bohring; Didier Lacombe; Fiona Stewart; Torunn Fiskerstrand; Laurence Bindoff; Siren Berland; Lesley C Adès; Michel Tchan; Albert David; Louise C Wilson; Raoul C M Hennekam; Dian Donnai; Sahar Mansour; Valérie Cormier-Daire; Stephen P Robertson
Journal:  Nat Genet       Date:  2008-12-14       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.